We held 1st China Pharma IP Summit 2016 on 17-18, November last year and confirmed more than 190 attendees from government agencies, in-house IP counsel, IP law firms, agencies and solution providers. The development of pharmaceutical industry heavily relies on their IP strategies, and this year pharmaceutical IP protection in China is drawing more attentions than before. Firstly, on 12th May 2017, the China Food and Drug Administration issued a proposal ( called 2017 Policy Notice No.55), which proposes to establish the patent linkage and amend the regulatory data protection regime. In the Notice No.55, it indicates the procedures of patent linkage and changes of regulatory data protection. Secondly, China is studying the drug patent extension reform, and the result may come out within this year. Additionally, the SIPO is amending PATENT LAW OF THE PEOPLE'S REPUBLIC OF CHINA and the new amendments to SIPO's Guidelines for Patent Examination has been effective since 1st April, 2017.

Based on above we will launch 2nd China Pharma IP Summit 2017 on 7th -8th December this year in Shanghai, and continue to provide a networking platform for industry peers.

Through the event, you can:

1. Follow updated policies in China, including patent linkage, regulatory data protection, patent extension reform, and the changes of Patent Law and Guidelines for Patent Examination.

2. Understand the latest examination standards and litigation proceedings in US and Europe

3. Learn excellent IP management cases

4. Meet you client fact to face and interacts with industry peers

The participants are mainly from pharma companies, biotech companies, law firms, IP/patent agencies, IP/patent solution providers, governments, relevant associations, research institutes. If you would like to attend or sponsor our summit, please feel free to call / email us to reserve your seats ASAP!

Thanks again for your attention and looking forward to your participation!


DAY 1 Morning

0730 Registration Open


Opening Remark

Day1 Chairman: Tony Chen, Partner, Jones Day


Updated Policies of Pharmaceutical/Biotechnology Patent Examination from SIPO

Pharmaceutical and Biological Invention Examination Department, SIPO (Inviting)


Tips for Successful Patenting of Pharmaceutical/Biotechnology Inventions From USPTO

Speaker is inviting


Topic is Confirming

Christopher T. Griffith, Founding Partner, Green, Griffith & Borg-Breen LLP

1030 Coffee Break


The Drug Patent Extension Reform in China----From a Perspective of China Innovation Drug Patent Protection Status

Deng Shengju, IP Director, Sihuan Pharm


Panel Discussion: The Patent Linkage Feasibility Study in China and Implementing Rules Evaluation

Oct. 30, 2016, Minister of CFDA Bi Jingquan emphasized that: “CFDA should strive to establish a drugs evaluation and approval system for encouraging innovation,......research a series of policies for clinical trial management, data protection and patent linkage that are closely related to the innovation”. On May 12, 2017, CFDA issued Circular No. 55 aimed to protect innovators' rights, and the first item is establishment of patent linkage system, which will have a significant impact on both innovative and generic drugs. When we establish patent linkage system, what factors should we take into consideration to make it more suitable for china phamaceutical industry? How to localize this system and make it more operable?


Tony Chen, Partner, Jones Day


Cheng Yongshun, Director, Beijing Intellectual Property Institute (Former Senior Judge and the Deputy Presiding Judge of the IP Division of Beijing High People’s Court)

Song Ruilin, Executive President,China Pharmaceutical Innovation and Research Development Association (Inviting)

1240 Lunch Buffet

DAY 1 Afternoon


Issues Likely to Arise Under Patent Linkage

● Cases that have been decided by US courts in applying the various timelines of the Hatch-Waxman Act.

● Benefits that have accrued to both generics and branded companies under the linkage regime.

Randall Rader, Former Chief Judge, the United States Court of Appeals for the Federal Circuit


Intellectual Property Management Experience from Multinational Pharmaceutical Company


Patent Invalidation Case Study

Shanghai Patent & Trademark Law Office, LLC

1545 Coffee Break


Topic is Confirming


Regulatory Data Protection Regime Changes in China and Impacts


Sponsored by NTD Intellectual Property Attorneys


Heather Lin, Senior Partner and Patent Attorney, NTD Intellectual Property Attorneys


Alvin Deng, Head of Intellectual Property, Novozymes China

Li Renjiu, IP Director, Luye Pharma Group Ltd

Christopher Shaowei, Senior Partner, NTD Patent & Trademark Agency

1820 End of Day 1

DAY 2 Morning

0840 Opening Remark


The Latest Developments of Patenting Pharmaceutical and Biotechnological Inventions at the EPO

The speaker will build up on his last year’s presentation and update more specifically on new case law and practice as regards patentability requirements for pharmaceuticals and biotechnological inventions, including the recent changes to the implementing regulations in respect of plant patenting. He will also update on other EPO developments such as the new opposition practice, IP5 developments (global dossier, extension of validation states and PPH)

Dieter Tzschoppe, Director Operations for Biotechnology / Pure and Applied Organic Chemistry, European Patent Office


Generic Product Launches - Preparing Strategies Which Address Global IP and Regulatory Issues

Yehudah Livneh, Strategic IP consultant; Former General Patent Counsel and VP Corporate IP and Legislative Affairs at Teva Pharmaceuticals


Patent Litigation in Europe

Sponsor Opportunity for Europe Law Firm

1030 Coffee Break


State of Play of Biosimilars in the Europe

History of development and registration

Dealing with exclusivity / patent litigation

Marketing strategies

Christof Bull, Associate General Patent Counsel, UCB Biopharma


Regulatory Data Protection Regime Changes in China and Impacts

1230 Lunch Buffet

DAY 2 Afternoon


Turning Your Patents Into Money: Structuring Licences: Key Issues to Watch Out for and Practical Tips

Ben Goodger, General Cousel, ASLAN Pharmaceuticals Pte Limited


Patent Management Case Study---- From R&D To Launch

Xu Shuwen, Legal Director, Guangzhou Baiyun Mountain Pharmaceutical Factory

1510 Coffee Break


Chinese Medicines Development Opportunities and IP Pretection Strategy

Speaker is Inviting


Analysis and Utilization of Drug Patent Information

Shou Jingjing, Associate Researcher, Intellectual Property Development & Research Center, SIPO

1650 Closing Remark


  Media Partner